Victor Moyo
Technik-/Wissenschafts-/F&E-Leiter bei TRAWS PHARMA, INC.
Profil
Victor Moyo is currently the Chief Medical Officer at Traws Pharma, Inc. since 2023 and at OncoPep, Inc. since 2022.
He holds a doctorate degree from the University of Zimbabwe.
Aktive Positionen von Victor Moyo
| Unternehmen | Position | Beginn |
|---|---|---|
| TRAWS PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 24.10.2023 |
OncoPep, Inc.
 OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Corporate Officer/Principal | 01.05.2022 |
Ausbildung von Victor Moyo
| University of Zimbabwe | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TRAWS PHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Finance |
